Drugs / QCC374
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02245828 | Jul 2014 → Dec 2015 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02939599 | Feb → Nov 2018 | pulmonary arterial hypertension | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02927366 | Sep 2017 → Jun 2018 | pulmonary arterial hypertension | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QCC374 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02927366 ↗ |
| Route | Inhaled | “This is a long-term open-label safety extension to the Phase 2a study of inhaled QCC374 in adult patients with PAH.” NCT02939599 ↗ |